Posted by Michael Wonder on 04 Jul 2016
Allergan receives positive opinion through European decentralised procedure for Belkyra (deoxycholic acid) for patients with submental fullness
1 July 2016 - Belkyra (deoxycholic acid) expected to be the first non-surgical prescription medicine to treat submental fullness (or double chin) to be authorised in 21 European Union Member States as well as Iceland and Norway.
Allergan today announced that it has received a positive opinion from the Swedish Medical Products Agency (MPA) for Belkyra (deoxycholic acid). Belkyra will be the first prescription medicine to be licensed in Europe for the treatment of moderate to severe convexity or fullness associated with submental fat (often called double chin) in adults when the presence of submental fat has a psychological impact for the patient.
Belkyra is being evaluated through the decentralised procedure, with the Swedish MPA acting as the reference member state for 20 other countries in the European Union, as well as Iceland and Norway.
